122 related articles for article (PubMed ID: 11020402)
1. How long a stay in the hospital is needed for patients with community-acquired pneumonia?
Siegel RE
Am J Med; 2000 Oct; 109(5):434-6. PubMed ID: 11020402
[No Abstract] [Full Text] [Related]
2. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
Restrepo MI; Frei CR
Am J Med; 2010 Apr; 123(4 Suppl):S39-46. PubMed ID: 20350634
[TBL] [Abstract][Full Text] [Related]
3. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia.
Fine MJ; Pratt HM; Obrosky DS; Lave JR; McIntosh LJ; Singer DE; Coley CM; Kapoor WN
Am J Med; 2000 Oct; 109(5):378-85. PubMed ID: 11020394
[TBL] [Abstract][Full Text] [Related]
4. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.
Cortoos PJ; Gilissen C; Laekeman G; Peetermans WE; Leenaers H; Vandorpe L; Simoens S
Scand J Infect Dis; 2013 Mar; 45(3):219-26. PubMed ID: 23113827
[TBL] [Abstract][Full Text] [Related]
5. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
Zhou QT; He B; Zhu H
Value Health; 2009; 12(1):40-6. PubMed ID: 18637052
[TBL] [Abstract][Full Text] [Related]
6. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.
Ramirez JA; Vargas S; Ritter GW; Brier ME; Wright A; Smith S; Newman D; Burke J; Mushtaq M; Huang A
Arch Intern Med; 1999 Nov; 159(20):2449-54. PubMed ID: 10665893
[TBL] [Abstract][Full Text] [Related]
7. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
Marras TK; Nopmaneejumruslers C; Chan CK
Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
[TBL] [Abstract][Full Text] [Related]
9. Effects of Hospital Practice Patterns for Antibiotic Administration for Pneumonia on Hospital Lengths of Stay and Costs.
Christensen EW; Spaulding AB; Pomputius WF; Grapentine SP
J Pediatric Infect Dis Soc; 2019 May; 8(2):115-121. PubMed ID: 29438527
[TBL] [Abstract][Full Text] [Related]
10. [Community-acquired pneumonia: influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio].
Fernández Alvarez R; Gullón Blanco JA; Rubinos Cuadrado G; Jiménez Sosa A; Hernández García C; Medina Gonzálvez A; González Martín I
Arch Bronconeumol; 2001 Oct; 37(9):366-70. PubMed ID: 11674935
[TBL] [Abstract][Full Text] [Related]
11. Approaches to drug therapy, formulary, and pathway management in a large community hospital.
Halley HJ
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S17-21. PubMed ID: 11098316
[TBL] [Abstract][Full Text] [Related]
12. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia.
Ramirez JA
Ann Pharmacother; 1998 Jan; 32(1):S22-6. PubMed ID: 9475836
[TBL] [Abstract][Full Text] [Related]
13. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
[TBL] [Abstract][Full Text] [Related]
14. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Clark LC; Davis CW
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
[TBL] [Abstract][Full Text] [Related]
15. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay.
Ehrenkranz NJ; Nerenberg DE; Shultz JM; Slater KC
Infect Control Hosp Epidemiol; 1992 Jan; 13(1):21-32. PubMed ID: 1580920
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
Kessler LA; Waterer GW; Barca R; Wunderink RG
Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
[TBL] [Abstract][Full Text] [Related]
17. Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP).
Kozma CM; Dickson M; Raut MK; Mody S; Fisher AC; Schein JR; Mackowiak JI
J Med Econ; 2010; 13(4):719-27. PubMed ID: 21091099
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.
Stein GE; Mantz SL
Hosp Pharm; 1995 Feb; 30(2):132-4, 137. PubMed ID: 10140526
[TBL] [Abstract][Full Text] [Related]
19. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
Rhew DC; Hackner D; Henderson L; Ellrodt AG; Weingarten SR
Chest; 1998 Jan; 113(1):142-6. PubMed ID: 9440581
[TBL] [Abstract][Full Text] [Related]
20. Community-acquired pneumonia. Cost-effective antimicrobial therapy.
Cunha BA
Postgrad Med; 1996 Jan; 99(1):109-10, 113-4, 117-9, passim. PubMed ID: 8539197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
